Tamoxifen Represses Breast Cancer Cell Growth by Interacting with SKI-interacting Protein (SKIP)
Tamoxifen is the most common choice of anti-cancer drug for breast cancer in pre-menopausal women. Tamoxifen antagonizes the estrogen proliferative effect by interacting with estrogen receptor. Despite the fact that this treatment has showed a tremendous effect on the survival of patients, resistance to the treatment frequently occurs. Several mechanisms of tamoxifen resistance have been already d